One-Stop care: hepatitis c treatment may curb HIV and opioid risks
NCT ID NCT03221309
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new way to care for people who inject drugs and have hepatitis C. Along with standard hepatitis C treatment, participants were offered HIV prevention medication and buprenorphine for opioid use disorder. The goal was to see if this combined approach could cure hepatitis C, reduce HIV risk, and support recovery. The study enrolled 198 adults with ongoing injection drug use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREP are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HIPS
Washington D.C., District of Columbia, 20002, United States
-
University of Maryland Drug Treatment Center
Batlimore, Maryland, 21223, United States